News

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...
While its shares have been lagging the market significantly, that could change in the next decade as financial results ...
These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
Detailed price information for Berkshire Hathaway Cl A (BRK-A-N) from The Globe and Mail including charting and trades.
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...
In light of this shifting landscape, investors seeking diversification would do well to consider three companies that stand out as prime potential beneficiaries of a rotation from tech to healthcare: ...
Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...
Tariffs, and their potential detrimental impacts on vehicle affordability, company profits, global competitiveness, and ...
SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...